Healthcare investment firm Vivo Capital held the final closing of its eight fund at $750m.
Investors in Vivo Capital Fund VIII include pension funds, financial institutions, endowments, foundations, family offices, and fund of funds. In addition to limited partners that participated in Vivo’s earlier funds, Vivo VIII added a number of new institutional investors from the U.S., Europe, and Asia.
Vivo VIII plans to invest primarily in later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China.
The firm plans to continue assisting companies in both countries in their efforts to forge cross-border partnerships, enabling them to acquire new products and expand the market for their existing products.
Vivo also intends to build companies from scratch, identifying later stage products with a high probability of FDA approval, and investing directly in public companies.
The firm, which has more than $1.7 billion total funds under management, has offices in Palo Alto, California, Beijing, and Shanghai, China.
FinSMEs
18/03/2015